Role of changes in dietary habits in polycystic ovary syndrome (Q35776468)

10 August 2017

1 reference

title

Role of changes in dietary habits in polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

10 August 2017

1 reference

1 reference

Renato Pasquali

1

1 reference

PubMed ID

15149567

10 August 2017

Alessandra Gambineri

series ordinal

2

1 reference

10 August 2017

1 April 2004

1 reference

Reproductive BioMedicine Online

10 August 2017

1 reference

10 August 2017

8

1 reference

10 August 2017

4

1 reference

10 August 2017

431-439

1 reference

High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk.

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Resumption of fertility with diet in overweight women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Insulin-lowering therapeutic modalities for polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Obesity and the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

The metabolic syndrome is related to beta 3-adrenoceptor sensitivity in visceral adipose tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Effects of weight loss on the hormonal profile in obese, infertile women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Hormonal responses to physical exercise in patients with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

The genetics of obesity. Lessons for polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Dietary fat and the regulation of energy intake in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Testosterone replacement therapy restores normal ghrelin in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Effect of exercise on insulin action in human skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Neuroendocrinology of the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Divergent effects of weight reduction and oral anticonception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Substrate competition and insulin action in animal models

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

Expression and localization of the leptin receptor in endocrine and neuroendocrine tissues of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960927-3

7 January 2021

10.1016/S1472-6483(10)60927-3

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15149567